|
|
|
|
|
|
|
|
|
|
|
|
|
28.01.26 - 16:03
|
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress (GlobeNewswire EN)
|
|
|
SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today issued a statement to address recent statements containing inaccurate and misleading claims regarding the Company's research programs, clinical progress, and operations....
|
|
|
|
|
|
|
13.01.26 - 14:03
|
CytoMed Therapeutics′ new year update and seeks shareholders′ feedback on proposal to improve shareholder value for their patient capital (GlobeNewswire EN)
|
|
|
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements, CytoMed through new subsidiary LongevityBank is also diversifying its product pipeline through the process development of clinical-grade cord blood-derived Natural Killer cells. In so doing, it will enhance access to rare and valuable cord blood as sources for cell-based allogeneic therapies. In addition to CytoMed's gamma delta T cells, Natural Killer cells also express receptors that recognise stress ligands, allowing them to be cytotoxic tools to combat a wide variety of solid and hematological cancer...
|
|
|
|
|
|
|
|
|
08.01.26 - 05:30
|
Midday Takeaway: HSI Down 322 pts; HSTI Down 64 pts; LENOVO GROUP Down over 5%; CK ASSET, CKI HOLDINGS, CLP HOLDINGS, SHINEWAY PHARM, BOC AVIATION Hit New Highs (AAStocks)
|
|
|
At midday close, HSI dropped 322 pts or 1.2% to 26,136. HSTI dropped 64 pts or 1.1% to 5,673. HSCEI fell 103 pts or 1.1% to 9,034.Active Heavyweights:MEITUAN (03690.HK) closed at $101.6, down 2.8%XIAOMI (01810.HK) closed at $37.48, down 1.8%TENCENT (00700.HK) closed at $614, down 1.7%BABA (09988.HK) closed at $143.7, down 1.5%PI......
|
|
|
|
|
05.01.26 - 14:33
|
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET....
|
|
|
|
|
|
|
10.12.25 - 03:54
|
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today the pricing of its previously announced underwritten public offering of 15,789,475 of its ordinary shares at a price to the public of $19.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 2,631,578 ordinary shares at an offering price of $18.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant....
|
|
|
|
|
09.12.25 - 20:42
|
What′s Going On With Wave Life Sciences Stock Tuesday? (Benzinga)
|
|
|
Wave Life Sciences rises after new WVE-007 weight-loss data and multiple analyst upgrades, alongside a $250 million offering announcement.
Latest Ratings for WVE
DateFirmActionFromTo Mar 2021SVB LeerinkReiteratesMarket Perform Dec 2020HC Wainwright & Co.AssumesBuy Oct 2020RBC CapitalInitiates Coverage OnSector Perform
View More Analyst Ratings for WVE
View the Latest Analyst Ratings
read more...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
